methylsulfasalazine
RN & N1 from 9th CI Form Index
Also Known As:
5-(4-(3-methyl-2-pyridylsulfamoyl)phenylazo)salicylic acid; methyl-SASP; methylsalazosulfapyridine; methylsalazosulphapyridine; 2-hydroxy-5-((4-(((3-methyl-2-pyridinyl)amino)sulfonyl)phenyl)azo)benzoic acid
Networked: 2
relevant articles (1 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
| 1. | Ulcerative Colitis
01/01/1979
- " It is concluded that methyl-SASP presents an improvement in the effect/side effect ratio when dealing with symptomatic ulcerative colitis. " 01/01/1979
- " It is concluded that whereas SASP showed a relapse-preventing effect in ulcerative colitis in this study comparable to that previously reported, the effect of methyl-SASP was only comparable to that of placebo, and the active substance in SASP does not seem to be unsplit SASP." 01/01/1979
- " Applying clinical symptoms (bowel movements, registered by the patients on special charts), clinical condition (assessed by the patient), proctoscopic signs, and registration of side effects, it is concluded that methyl-SASP had an effect on ulcerative colitis indistinguishable from that of SASP. " 01/01/1979
- " In an attempt to improve the ratio between therapeutic effect and side effects of salazosulphapyridine (SASP), methyl-salazosulphapyridine (methyl-SASP) was compared with SASP in a randomized controlled double-blind trial, without cross-over, in patients with active ulcerative colitis. "
|
|
Related Drugs and Biologics